Calidi Biotherapeutics (CLDI) CFO Andrew C. Jackson Receives Option Grant

What Happened Andrew C. Jackson, Chief Financial Officer of Calidi Biotherapeutics (CLDI), received a grant of 14,000 incentive stock options on August 17, 2026. The options have an exercise price of $1.36 per share (equal to the closing stock price on the grant date). This was a compensation award (derivative grant), not a purchase or sale of shares, and was granted under the Issuer’s 2023 Equity Incentive Plan.

Key Details

• Transaction date: August 17, 2026 (reported on Form 4 filed Aug 19, 2026).
• Grant: 14,000 incentive stock options; exercise price $1.36 per share.
• Vesting: 25% vests on the one-year anniversary (08/17/2027); remaining 75% vests monthly in 1/36th installments thereafter (i.e., over the following 36 months), subject to continued service.
• Transaction type: Award/Grant (derivative); transaction reported as exempt under Rule 16b-3.
• Shares owned after transaction: not specified in the filing.
• Footnote: filing notes the grant does not include incentive stock options previously granted to the Reporting Person.

Context This was a standard equity compensation grant for retention/incentive purposes. The options were not exercised or sold; they are subject to multi-year vesting and will only become exercisable as they vest. Because the exercise price equals the market close on the grant date and the award was made under a shareholder-approved plan (Rule 16b-3), the transaction is a routine executive compensation event rather than an immediate market bet by the insider.